Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone by Johnsen, Erik et al.
RESEARCH ARTICLE Open Access
Effectiveness of second-generation antipsychotics:
a naturalistic, randomized comparison of
olanzapine, quetiapine, risperidone, and
ziprasidone
Erik Johnsen
1*, Rune A Kroken
1, Tore Wentzel-Larsen
2, Hugo A Jørgensen
1,3
Abstract
Background: No clear recommendations exist regarding which antipsychotic drug should be prescribed first for a
patient suffering from psychosis. The primary aims of this naturalistic study were to assess the head-to-head
effectiveness of first-line second-generation antipsychotics with regards to time until drug discontinuation, duration
of index admission, time until readmission, change of psychopathology scores and tolerability outcomes.
Methods: Patients ≥ 18 years of age admitted to the emergency ward for symptoms of psychosis were
consecutively randomized to risperidone (n = 53), olanzapine (n = 52), quetiapine (n = 50), or ziprasidone (n = 58),
and followed for up to 2 years.
Results: A total of 213 patients were included, of which 68% were males. The sample represented a diverse
population suffering from psychosis. At admittance the mean Positive and Negative Syndrome Scale (PANSS) total
score was 74 points and 44% were antipsychotic drug naïve. The primary intention-to-treat analyses revealed no
substantial differences between the drugs regarding the times until discontinuation of initial drug, until discharge
from index admission, or until readmission. Quetiapine was superior to risperidone and olanzapine in reducing the
PANSS total score and the positive subscore. Quetiapine was superior to the other drugs in decreasing the PANSS
general psychopathology subscore; in decreasing the Clinical Global Impression - Severity of Illness scale score
(CGI-S); and in increasing the Global Assessment of Functioning - Split version, Functions scale score (GAF-F).
Ziprasidone was superior to risperidone in decreasing the PANSS positive symptoms subscore and the CGI-S score,
and in increasing the GAF-F score. The drugs performed equally with regards to most tolerability outcomes except
a higher increase of hip-circumference per day for olanzapine compared to risperidone, and more galactorrhoea
for risperidone compared to the other groups.
Conclusions: Quetiapine appears to be a good starting drug candidate in this sample of patients admitted to
hospital for symptoms of psychosis.
Trial Registration: ClinicalTrials.gov ID; URL: http://www.clinicaltrials.gov/: NCT00932529
Background
For a patient suffering from psychosis, most second-gen-
eration antipsychotics (SGAs) have been considered first-
line agents based on their more favorable tolerability
profiles compared with older first-generation drugs [1-4].
This particularly applies to first episode psychosis [1,3].
Most treatment guidelines are centered on schizophrenia,
and the empirical evidence is very limited for non-schizo-
phrenic psychotic disorders [5]. Differential antipsychotic
efficacy of the first-line antipsychotics remains to be con-
vincingly demonstrated despite their differing pharmaco-
logical properties. The lack of differences regarding
efficacy may be caused by limitations of the evidence
base. The highly selected samples and rigid experimental
designs of traditional randomized, controlled trials may
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mation [6]. Contradictory results in studies from different
sources of pharmaceutical sponsorship may also contri-
bute to the inconclusiveness of the evidence [7].
In recent years, several studies of the effectiveness of
antipsychotics have been launched to address some of the
limitations associated with traditional randomized con-
trolled trials (RCTs) of efficacy. Effectiveness trials, also
known as “naturalistic”, “real-life”, “pragmatic”,o r“practi-
cal” trials, address how a treatment works under normal
clinical circumstances as distinct from the somewhat arti-
ficial settings of the efficacy trials [6]. Through pragmatic
designs and more global outcome measures, these trials
have been expected to supplement the base of evidence
regarding effectiveness of antipsychotics. The larger stu-
dies have been financially sponsored by noncommercial
sources, addressing also the problem of funding bias. In a
recent systematic review of randomized head-to-head
comparisons of the effectiveness of SGAs, differences
among the SGAs were only consistent across trials for a
limited number of outcomes [8]. In patients with chronic
psychosis, olanzapine patients took a longer time to dis-
continuation of treatment and had better treatment adher-
ence compared with other SGAs, but this treatment was
also associated with more adverse metabolic effects. The
psychopathology and most tolerability outcomes were
otherwise surprisingly equal among groups. However, a
significant finding in the review of effectiveness trials was
a very high drug discontinuation rate in a short-term per-
spective for all the SGAs. About three-quarters of the
patients had discontinued their allocated SGA within 18
months, with a median time until discontinuation of 5.5
months as found in the CATIE study [9]. To the authors’
best knowledge, trials of the comparative effectiveness of
SGAs have focused solely on the period during which the
patients have used their allocated drugs. By this strategy,
the results remain equivocal and do not supplement the
evidence base regarding effectiveness as expected. An
alternative strategy would be to assess antipsychotic effec-
tiveness in a period extended beyond use of the first-
assigned drug. Given the frequently chronic nature of schi-
zophrenia and related disorders, and taking into account
the new findings on discontinuation rates, the antipsycho-
tic drug regimen at a given time is likely to be part of a
sequence of antipsychotics. The principal question in this
strategy addresses which SGA should be the starting drug
in order to provide the most beneficial outcome of anti-
psychotic treatment.
Aims of the study
The aim of the present study was to assess antipsychotic




The Bergen Psychosis Project (BPP) is a 24-month, pro-
spective, rater-blind, naturalistic, randomized, head-to-
head comparison of the effectiveness of olanzapine,
quetiapine, risperidone, and ziprasidone. All patients
were recruited from the Division of Psychiatry at Hau-
keland University Hospital with a catchment population
of about 400000. The BPP was approved by the Regional
Committee for Medical Research Ethics, and the Norwe-
gian Social Science Data Services. Funding of the project
was initiated by the Research Council of Norway, fol-
lowed by Haukeland University Hospital, Division of
Psychiatry. The BPP has not received any financial or
other support from the pharmaceutical industry.
Patients
The Regional Committee for Medical Research Ethics
allowed eligible patients to be included before informed
consent was provided, thus entailing a clinically relevant
representation in the study. In medical research the provi-
sion of informed consent from the participants is funda-
mental. The disqualification of the most gravely ill patients
from participating in trials represents an ethical dilemma;
however, as these patients will most likely receive the
drugs once they are approved for marketing, despite the
lack of evidence from this population. Trial inclusion of
patients without informed consent is justifiable on 2 con-
ditions: That no other context exists in which the research
question can be answered, and that all patients get clear
clinical benefit from whatever treatment they are allocated
to [10]. These criteria are fulfilled in some mental condi-
tions from which important studies have been published
[11,12]. Patients (age ≥ 18 years) were eligible for the
s t u d yi ft h e yw e r ea d m i t t e dt ot h ee m e r g e n c yw a r df o r
symptoms of psychosis as determined by a score of ≥ 4o n
one or more of the items Delusions, Hallucinatory beha-
vior, Grandiosity, Suspiciousness/persecution, or Unusual
thought content in the Positive and Negative Syndrome
Scale (PANSS) [13], and were candidates for oral antipsy-
chotic drug therapy. Eligible patients met ICD-10 [14]
diagnostic criteria for schizophrenia, schizoaffective disor-
der, schizophreniform disorder, brief psychotic episode,
delusional disorder, drug-induced psychosis, and major
depressive disorder with psychotic features. The diagnoses
were determined by experienced clinicians. Patients were
excluded from the study if they were unable to use oral
antipsychotics, were suffering from manic psychosis, were
unable to cooperate reliably during investigations, did not
understand spoken Norwegian language, were candidates
for electroconvulsive therapy, or were medicated with clo-
zapine on admittance. Patients with drug-induced psy-
choses were included only when the condition did not
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therapy was indicated.
Treatments
The evidence thus far shows that to prospectively pre-
dict which antipsychotic might be optimal for a given
patient with regards to effect and tolerability is not pos-
sible, and that antipsychotic therapy currently involves a
trial and error approach [15]. A prior history of antipsy-
chotic drug use may provide some information, though.
Taking these factors into account the BPP protocol
mimicked the normal clinical situation in which oral
antipsychotic drug therapy is initiated, with one excep-
tion: At admission, a sealed and numbered envelope was
opened by the attending psychiatrist and then the
patient was offered the first drug in a random sequence
of the first-line antipsychotics in Norway - olanzapine,
quetiapine, risperidone, or ziprasidone. The randomiza-
tion was open to the treating psychiatrist or physician
and to the patient. Both the treating clinician and/or the
patient could discard the SGA listed as number 1 on
the list because of medical contraindications for the use
of, or prior negative experiences with the drug, however,
and the next on the list could be chosen. The same
principle was followed if the next drug could not be
used. A reason for discarding drugs was sought. In each
sequence, the SGA listed as 1 defined the randomization
group (RG). The actual SGA chosen, regardless of ran-
domization group, defined the first-choice group (FCG).
Further dosing, combination with other drugs, or
switching to another antipsy c h o t i cd r u gw e r et h e nl e f t
at the clinician’s discretion. Apart from sporadic use,
the patients in the project could use only one antipsy-
chotic drug except during the cross-taper period asso-
c i a t e dw i t hac h a n g eo fa n t i p s y c h o t i cd r u g .T h i si si n
correspondence with leading treatment guidelines which
mention combinations of anti p s y c h o t i c so n l ya sal a s t
resort. In cases where concomitant use of more than
one antipsychotic drug was found inevitable, the patient
was excluded from the project. Any investigation that
was beyond normal clinical practice was introduced only
after informed consent was obtained.
Assessments
Study visits were at baseline, at discharge or at 6 weeks
from baseline at the latest, and at 3, 6, 12, and 24
months from baseline.
All assessments were performed by one trained inves-
tigator. Before inclusion, eligible patients were inter-
viewed by the investigator, using the PANSS, the
Calgary Depression Scale for Schizophrenia (CDSS) [16],
and the Clinical Drug and Alcohol Use Scales (CDUS/
CAUS) [17], and were rated according to the Clinical
Global Impression–Severity of Illness scale (CGI-S) [18],
and the Global Assessment of Functioning–Split Ver-
sion, Functions scale (GAF-F) [19]. The patients
received a physical examination by the admitting physi-
cian, and standard blood samples were collected accord-
ing to the hospital’s routine. At discharge from the
hospital or at 6 weeks if not discharged, the tests and
examinations were repeated by the rater who was una-
ware of the treatment. Patients were asked also to com-
plete the patient-administered version of the UKU Side
Effect Rating Scale (UKU-SERS Pat) [20], and serum
level measurements of the antipsychotics were con-
ducted. Thus far, all investigations and tests were part
of the hospital’s routine for the management of patients
suffering from psychosis and became part of the
patient’s medical record. At this point, the patients were
asked for informed consent to be contacted and
included in the follow-up project.
At follow-up visits 3, 6, 12, and 24 months after base-
line, measures of psychopathology, function, and toler-
ability, as well as clinical and laboratory assessments
were repeated by the rater blind to treatment.
The global outcomes measures were: the time until
discontinuation of the initial SGA for any cause, the
time until discharge from index hospitalization, and the
time until readmittance to the emergency ward for any
reason. Symptoms were assessed by the PANSS, the
CDSS, the CGI-S, and the GAF-F. Tolerability was mea-
sured by the UKU-SERS-Pat, physical examinations, and
laboratory tests. The repeated physical examinations
included Body Mass Index (BMI), waist and hip circum-
ferences, and blood pressure. Laboratory tests included
electrocardiogram (ECG) and blood tests on glucose,
lipids, prolactin, and liver functions. The patients were
fasting before the drawing of blood, as defined by no
intake of food or caloric drink during the preceding 9
hours.
At each visit, all medications were recorded, and the
mean antipsychotic drug doses were calculated. Antipsy-
chotic drug doses for antipsychotics other than the
SGAs were converted to chlorpromazine equivalent
doses [21]. In cases were chlorpromazine equivalent
doses could not be found in the literature, this was done
by conversion to defined daily doses (DDDs) as devel-
oped by the World Health Organization Collaborating
Centre for Drug Statistics Methodology [22]. The basic
definition of the DDD unit is the assumed average
m a i n t e n a n c ed o s ep e rd a yf o rad r u gu s e df o ri t sm a i n
indication in adults.
Statistical procedures
The primary analyses were intention-to-treat (ITT) ana-
lyses based on the randomization groups (RGs), that is
trial participants were analyzed in the group to which
they were randomized regardless of which treatment they
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[23]. Secondary analyses were based on first choice
g r o u p s( F C G s ) .B a s e l i n ed a t ao fF C G sw e r ea n a l y z e d
using SPSS software, version 15 (SPSS, Chicago, IL), and
by means of exact c
2 tests for categorical data and one-
way ANOVAs for continuous data. For multiple compar-
isons, Benjamini-Hochberg adjustments were applied.
For continuous data that were not approximately nor-
mally distributed, a Kruskal-Wallis nonparametric test
was used. For baseline comparisons between those lost to
follow-up before retesting and those who were retested,
independent samples T-tests were used for continuous
data and exact c
2 tests for categorical data.
Global outcomes were analyzed using SPSS, version
15, with Kaplan-Meier analyses of survival. Change of
symptoms and tolerability outcomes were analyzed in R
by means of linear mixed effects (LME) models [24,25].
Fixed effects, i.e. systematic differences between the
drugs, were different linear slopes in the four treatment
groups, technically a group by time interaction with no
baseline group differences. The model calculates overall
change per time unit for the variables in the follow-up
period that can be visually represented by the slope of a
linear curve with time on the x axis and the respective
variable on the y axis. The target of the present study
was to investigate the over-all change during the follow-
up period and the LME model was considered the ana-
lysis of choice for this purpose. The model uses all avail-
able data and handles different numbers of visits by
individual patients, as well as differences in times
between visits. Furthermore, the mixed effects model
has demonstrated superior statistical power when the
missing data is non-ignorable [26]. A linear slope for
the follow-up period may represent an over-simplifica-
tion, however, as it does not capture slope differences at
different times. Based on results from other effectiveness
studies symptom changes typically follow an initial steep
decline followed by a flatter curve [9,27]. LME sensitiv-
ity analyses were therefore undertaken separately for the
steep and for the flat part of the symptom curves. The
choice of period corresponding to the steep and flat part
was derived from visual information from plots of the
individual symptom curves. The draw-back of dividing
the follow-up is loss of statistical power and hence risks
of statistical type II errors.
Symptom ratings, laboratory tests and physical examina-
tions were administered on all visits. The UKU-SERS-Pat
was administered at visit 2 and following visits. Because
differences between treatment groups on UKU-SERS-Pat
measures could theoretically be present at visit 2, this was
allowed for in the statistical model. For multiple compari-
sons, Benjamini-Hochberg adjustments were applied. The
level of statistical significance was set at a =0 . 0 5 .
Results
The patient enrolment is displayed in Figure 1. A total
of 213 patients were allocated to randomized sequences
of the first-line SGAs listed from 1 to 4. The SGAs
listed as 1 defined the randomization groups (RGs).
A total of 173 (81.2%) patients received the SGA listed
as 1, whereas 39 (18.3%) chose another SGA on the list.
The choice of SGA was unknown for one patient. There
were no differences among RGs in the fractions of
patients that did not choose the SGA listed as 1.
Primary outcomes - ITT analyses based on RGs
Baseline demographic and clinical characteristics are pre-
sented in Additional file 1. There were no substantial dif-
ferences between the randomization groups regarding
proportions with life-time antipsychotic drug exposure,
or proportions that had used antipsychotic drugs in the
12 months prior to admittance or in the antipsychotic
agents used in that period. There were generally no sub-
stantial differences on baseline clinical or demographic
characteristics between those who were lost to follow-up
before retesting and those who were retested, with the
exception of a slightly higher PANSS negative subscore
for those lost to follow up (20.9 vs. 18.1 points (indepen-
dent samples T-Test: p = 0.007; mean difference 2.75
points; 95% confidence interval (CI) 0.74-4.75)).
Global outcomes
Times until discontinuation of the first offered antipsy-
chotic drug, until discharge from index admission, and
from discharge from index admission until readmission,
were not different among RGs (Figures 2, 3, and 4).
Symptom outcomes
Outcomes related to symptom reduction and increased
functioning are shown in Additional file 2 and Figures 5
and 6. There were significant differences among SGAs
as quetiapine was superior to risperidone and olanzapine
in reducing the PANSS total score and the positive sub-
score. Quetiapine was superior to the other drugs in
decreasing the PANSS general psychopathology sub-
score; in decreasing the CGI-S; and in increasing the
GAF-F score. Ziprasidone was superior to risperidone in
decreasing the PANSS positive symptoms subscore and
the CGI-S score, and in increasing the GAF-F score.
Curves for each individual regarding the PANSS total
score revealed a steeper decline initially as compared to
later in the follow-up period (curves not shown). Curves
for each individual on the other outcomes followed the
same general pattern, with the slope being steepest initi-
ally (curves not shown). The sensitivity analyses in sepa-
rate follow-up periods were performed from baseline to
90 days, corresponding to the steep part of the course,
and after 90 days, corresponding to the flatter part of
the course. The analyses revealed trends for the RGs
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whole 2-year follow-up (data not shown). Before 90 days
quetiapine and ziprasidone were superior to risperidone
in increasing the GAF-F score (LME: p < 0.05, unad-
justed for multiple comparisons), and quetiapine was
superior to risperidone in reducing the CGI-S score
(LME: p < 0.05, unadjusted for multiple comparisons).
The differences were no longer statistically significant
after adjusting for multiple comparisons.
Sensitivity analyses that adjusted for numerically higher
proportions of antipsychotic naïve patients in the quetia-
pine and ziprasidone RGs, revealed essentially identical
results with regards to symptom reduction and
increased functioning. Sensitivity analyses that excluded
patients with drug-induced psychoses revealed
essentially identical results with regards to symptom
reduction and increased functioning.
Tolerability outcomes
There were differences among the drugs for only a lim-
ited number of tolerability outcomes (Additional file 3).
Secondary outcomes - analyses based on FCGs
There were generally no substantial differences among
FCGs on baseline demographic and clinical characteris-
tics with the exception of a slightly higher PANSS posi-
tive subscore for olanzapine (21.3 points) compared with
risperidone (18.5 points) (one-way ANOVA: p = 0.007;
mean difference 2.8 points; 95% CI -5.0- -0.5). The mean
doses in milligrams per day with standard deviations
(SD) were 3.3 (1.2) for risperidone, 14.5 (5.2) for
Figure 1 Flow of patients through the study. Not meeting inclusion criteria = Score below 4 on all the items Delusions, Hallucinatory
behaviour, Grandiosity, Suspiciousness/persecution, or Unusual thought content in the Positive and Negative Syndrome Scale (PANSS); Uncoop.
= the patient was not able or willing to cooperate with testing and assessments; Organic braindis. = Organic brain disorder, principally
dementia; Randomization not acceptable = patient or treating clinician not willing to change existing antipsychotic medication; Administrative
causes = principally patient discharged before assessments could be made.
1 Enrolment started March 2003 until 2008, week 26. Full details on
enrolment were only registered from 2006, week 31 until 2008, week 26. Consequently only percentages are displayed for patients assessed for
eligibility and excluded patients.
2 Before discharge/6 weeks.
3 One patient in the risperidone and olanzapine groups missed the first follow-up
visit, but was retested on later visits.
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Page 5 of 13olanzapine, 357.0 (187.2) for quetiapine, and 101.3 (44.7)
for ziprasidone treated groups. The mean serum levels in
nanomoles per liter with SD were 82.4 (56.9) for risperi-
done, 102.4 (75.1) for olanzapine, 419.7 (544.9) for que-
tiapine, and 173.8 (81.4) for ziprasidone. The reference
ranges were 30-120, 30-200, 100-800, and 30-200 for ris-
peridone, olanzapine, quetiapine, and ziprasidone,
respectively. A total of 24 (24.7%) patients changed their
first-chosen SGA during follow-up. There were no differ-
ences among the FCGs in the rates of change or choice
of new antipsychotic drug. One or more doses of low-
potency first-generation antipsychotics were given to 15
patients (15.8%). There were no differences among the
FCGs in the number of patients receiving additional anti-
psychotics or the mean daily additional antipsychotic
dose in chlorpromazine equivalents. Seventy-one (74.7%),
23 (24.2%), and 7 (7.4%) patients received additional ben-
zodiazepines, antidepressants, and mood stabilizers,
respectively. In 30 (39.5%) of these patients 2 or more of
the additional psychotropics were used in combinations.
There were no differences among FCGs in the use of
these additional psychotropics. Anticholinergics were
prescribed for 6 (27.3%) of risperidone treated FCGs. The
corresponding figures were 1 (3.8%) for olanzapine, 0 for
quetiapine, and 3 (13.0%) for ziprasidone-treated FCGs
(exact c
2 t e s t :p=0 . 0 1 0 ) .T h e r ew e r en od i f f e r e n c e s
among FCGs in the rates of users of antipsychotics the
year prior to index hospitalization.
Global outcomes
The time until discontinuation of the initially chosen
SGA was significantly different among FCGs (log rank
test: p = 0.028). In subanalyses, patients with olanzapine
showed a longer time until discontinuation compared
with those treated with ziprasidone (log rank test:
p = 0.007), but not compared with the quetiapine and
risperidone groups. Times until discharge from index
admission and until readmission were not different
among FCGs.
Symptom outcomes
Symptom reduction outcomes were not substantially dif-
ferent from those of the primary analyses (Additional
file 2). The exception was for the ziprasidone
Figure 2 Survival functions. Time to discontinuation = Time (days) until discontinuation of first antipsychotic drug since index admission.
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ferent for the change of the PANSS positive subscore,
the GAF-F score, and the CGI-S score. Sensitivity ana-
lyses before 90 days in the FCGs revealed trends similar
to the ones from the ITT-analyses for the PANSS total
and subscores, with the quetiapine group having the
steepest slope, though not statistically significant. Olan-
zapine and quetiapine were superior to risperidone and
ziprasidone in increasing the GAF-F score before 90
days (LME: p < 0.05 adjusted for multiple comparisons).
Olanzapine was superior to risperidone and ziprasidone
in reducing the CGI-S score (LME: p < 0.05 adjusted for
multiple comparisons). In the analyses in the period
after 90 days the other groups were superior to risperi-
done regarding increase oft h eG A F - Fs c o r e( L M E :p<
0.05 adjusted for multiple comparisons).
Tolerability outcomes
Baseline registrations of laboratory measures were not
different in FCGs with the exception of a higher baseline
prolactin level for risperidone (Mean 746.8 IU/L) com-
pared with quetiapine (one-way ANOVA: p = 0.001;
mean diffence 401.4 IU/L; 95% CI 128.1-674.6) and zipra-
sidone (one-way ANOVA: p = 0.017; mean difference IU/
L 293.3; 95% CI 35.9-550.6). With regards to UKU-SERS-
Pat outcomes the only statistically significant difference
between FCGs was less decrease of sexual desire in the
ziprasidone group compared to the olanzapine group
(LME: p = 0.026). Regarding physical and laboratory
measures the following comparisons revealed statistically
significant differences (LME:p<0 . 0 5 ) :T h ez i p r a s i d o n e
group had the largest increase of triglycerides per day
compared to the other groups. The risperidone group
had larger increase of body weight per day than the olan-
zapine and quetiapine groups; as well as larger increase
per day of BMI compared to the olanzapine group.
Discussion
The study represents a naturalistic approach to the issue
of effectiveness among first-choice SGAs and which of
these should be preferred for a patient suffering from
psychosis. About two-thirds were males, fifty-three per-
cent represented first-time admittances, and 44% were
Figure 3 Survival functions. Time to discharge from index admission = Time (days) until hospital discharge after index hospital admission.
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at baseline was 74, range 51-110. The sample thus
represents a heterogeneous group of patients with psy-
chosis. The mean daily doses of the SGAs were in the
lower end of the therapeutic range with large standard
deviations, probably reflecting the relatively high propor-
tion of drug-naïve patients who in general respond to
lower doses of antipsychotic drugs.
Global outcomes
The SGAs performed equally in the ITT analyses regard-
ing times until discontinuation of the first offered anti-
psychotic drug, until discharge from index admission,
and until readmission. Olanzapine-treated FCGs showed
a significantly longer time to discontinuation compared
with the ziprasidone-treated FCGs in the secondary ana-
lyses. Superior drug survival or better adherence for
patients treated with olanzapine was also found in the
systematic review on head-to-head effectiveness of SGAs,
but only in chronic patients [9,28-30]. In one study on
chronic patients who had discontinued perphenazine,
both olanzapine and quetiapine groups had significantly
longer time until treatment discontinuation than risperi-
done [30]. In the EUFEST study comparing haloperidol
with SGAs in first-episode psychosis differences in all-
cause discontinuation risk were lower with amisulpride,
olanzapine, quetiapine, and ziprasidone, compared with
haloperidol [27]. Because our sample consisted of both
first-episode and chronically ill patients it seems reason-
able that our results regarding drug survival was inter-
mediate between those from chronic phase and first-
episode studies. Alternatively the limited N in our study
could represent a risk of a statistical type I error because
of inadequate power, and we may accordingly have
missed further differences among the groups.
Symptom reduction
The outcomes for symptom reduction were unexpected.
Quetiapine was consistently superior for all outcomes
except reduction of PANSS negative symptoms and
depressive symptoms according to CDSS. The mean
CDSS baseline score was rather low, however. The
results were similar for both RGs and FCGs, and their
validity is further strengthened by the inherent consis-
tency among outcomes on different rating scales, and
that similar trends were found in supplemental analyses
before and after 90 days. The latter analyses only
revealed a few statistically significant differences
Figure 4 Survival functions. Time to rehospitalisation = Time (days) until rehospitalisation after discharge from index admission.
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power in the supplemental analyses. To the authors’
best knowledge, this is the first effectiveness study to
show such differences among SGAs. In the systematic
review on antipsychotic effectiveness the SGAs per-
formed equally regarding their ability to alleviate symp-
toms of psychosis in all the acute phase studies
including studies on first-episode patients, and in all but
one chronic phase study [8,28-40]. The latter study
found olanzapine to be superior to quetiapine in chronic
schizophrenia patients that had previously discontinued
an SGA because of intolerability [29]. In one study que-
tiapine performed better than risperidone on depression
outcomes [36]. In the EUFEST study there were no dif-
ferences between the treatment groups with regards to
the PANSS and CDSS scores [27]. There were signifi-
cant differences for the CGI and GAF scores, and ami-
sulpride had the most favorable and haloperidol the
least favorable outcomes in this regard. In the CUtLASS
study comparisons between FGAs versus SGAs revealed
no differences between the groups with regards to the
PANSS, GAF, and CDSS scores [41]. In our study the
quetiapine and ziprasidone treated RGs had higher per-
centages of antipsychotic drug naïve patients, defined as
having no life-time exposure to antipsychotic drugs, at
baseline compared to the other groups. Hypothetically,
this could influence the results as the response to anti-
psychotics is usually better for first episode patient com-
pared to chronic multi-episode patients. The differences
between groups regarding fractions of antipsychotic
drug naïve patients were not statistically significant,
however, and additional sensitivity analyses revealed
essentially the same results. We have not been able to
find any differences in baseline demographic or clinical
characteristics that could introduce a systematic bias to
the results. In the secondary analyses based on FCGs
the only significant difference among the drugs was a
slightly higher PANSS positive score for the olanzapine
group at baseline. As the outcome measure is reduction
of PANSS positive score per day, the expected bias
could actually be in favor of olanzapine as a higher base-
line score has a higher potential for decrease. One could
argue that given the naturalistic design with assessments
not restricted to the time frame of actual use of the first
SGA, the outcomes may not be related to that particular
SGA but to subsequent medications. We have, however,
demonstrated that about three-quarters of the patients
did not change their original SGA, and that there were
Figure 5 Reduction of PANSS total score. Linear mixed effects model curves. Linear slopes for the randomization groups generated based
on linear mixed effects models PANSS total score output as displayed in Additional file 2 for risperidone, olanzapine, quetiapine, and
ziprasidone, respectively. The curves are confined to the first 300 days because the major bulk of data is obtained before 300 days.
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Page 9 of 13Figure 6 Change of PANSS subscores, CDSS, GAF-F, and CGI-S scores. The curves are generated based on drug-specific linear mixed effects
slopes as displayed in Additional file 2 for risperidone, olanzapine, quetiapine, and ziprasidone, respectively. PANSS = the Positive and Negative
Syndrome Scale; CDSS = the Calgary Depression Scale for Schizophrenia; GAF-F = the Global Assessment of Functioning scale - Split Version,
Functions scale; CGI-S = the Clinical Global Impression - Severity of Illness Scale. The curves are confined to the first 300 days because the major
bulk of data is obtained before 300 days.
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Page 10 of 13no differences among groups in the rate of antipsychotic
medication changes or the choice of a new antipsychotic
agent for those who did change. Furthermore, time until
discontinuation was generally the same for all SGAs
with the exception of olanzapine- versus ziprasidone-
treated FCGs. Nor were there any differences in
prescription rates of concomitant benzodiazepines, anti-
depressants, additional antipsychotics, or mood
stabilizers.
Tolerability
The outcomes for tolerability were generally the same
across groups. This is consistent with the findings of other
effectiveness studies in which the SGAs performed equally
on most tolerability outcomes [9,28-40]. The most consis-
tent difference between the SGAs across studies in the sys-
tematic review where related to weight gain and adverse
influence on cholesterol and triglyceride levels [8]. In the
EUFEST study there were only differences between halo-
peridol, amisulpride, olanzapine, quetiapine, and ziprasi-
done with regards to akathisia, parkinsonism, weight gain
from baseline, and hyperprolactinemia [27]. Whereas
there were no significant differences between the drugs
with regards to sexual dysfunction, prevalence of over-
weight, weight gain > 7% from baseline, proportions with
hyperglycemia, hypercholesterolemia, low HDL concentra-
tion, high LDL concentration, triglyceride concentration,
or change from baseline of these metabolic variables,
change from baseline of fasting insulin, or proportion with
QTc interval prolongation [27]. In the CutLASS study no
significant differences were found between FGA and SGA
groups [41]. The results may suggest that clear-cut side-
effect profiles from premarketing RCTs are less distinct in
a naturalistic setting where samples are more heteroge-
neous and concomitant medications less restricted. Our
secondary outcomes on metabolic effects were somewhat
surprising as the olanzapine-treated FCG was the only
group that had a reduction of triglycerides, and even
though patients in all FCGs gained weight and BMI, olan-
zapine-treated patients did so to a lesser degree than those
in the other groups. One explanation may be that there is
ah i g ha w a r e n e s sa m o n gc l i n i cians of olanzapine-asso-
ciated metabolic adverse effects and that patients at risk of
massive weight gain were identified very early and changed
to another antipsychotic agent. Obviously, interactions
with concomitant psychotropic drugs may also confuse
the picture. The finding of equality among FCGs regarding
neurological side effects must be interpreted bearing in
mind that there was a significant difference among FCGs
in the use of anti-cholinergic drugs, with the risperidone-
treated patients having the highest rate of anti-cholinergic
prescriptions. The finding of equality among FCGs regard-
ing prolactin elevation should also be interpreted in light
of the significantly higher baseline prolactin level in
risperidone-treated patients compared with patients in
both quetiapine-and ziprasidone-treated groups. The out-
comes for autonomic side effects should be interpreted
with caution because of their borderline internal reliability.
Limitations
Some limitations to the study need to be discussed. The
randomization was open to both the treating clinician and
the patient. Systematic utilization differences among the
SGAs before the start of the study could theoretically have
introduced bias if some of the SGAs under investigation
were associated with more prior experience among the
RGs. The direction of such theoretical bias is hard to pre-
dict, as both negative and positive prior experiences could
influence the attitude towards the SGAs under investiga-
tion. We registered prior life-time use of antipsychotic
drugs as a “yes” or “no” variable. The registration of anti-
psychotic drug use in the 12 months prior to study inclu-
sion was limited to whether or not antipsychotics were
used, and if so, which antipsychotic drug was used. Even
though more detailed information on the duration of this
treatment would have added value to the paper; that was
not the primary target of the study. There were, however,
no substantial differences between the RGs regarding pro-
portions with life-time exposure to antipsychotic drugs or
with regards to the agents used in the 12 months prior to
inclusion. Furthermore, there were no substantial differ-
ences between the randomization groups regarding the
proportion who accepted the SGA listed as 1. Theoreti-
cally, the open design could also introduce bias if some of
the SGAs were more popular among the clinicians or
patients. However, we have no clear indications of any
trends in the choices of SGAs or later changes.
Even though the exclusion criteria were limited com-
pared with those in RCTs for efficacy, the sample repre-
sents only about 30% of those assessed for eligibility
which could be a source of selection bias. Others have
found the proportion of patients included in clinical
trials to be in the range of 7%-14% of those initially
assessed [42-44]. At least at the lower end of this range,
the inference of trial results to the whole population
under investigation can be questioned.
There was a high attrition rate in the study, which
c o u l db eas o u r c eo fb i a si fa t t r i t i o nw a ss i g n i f i c a n t l y
different in the treatment groups. However, we found
no significant difference in total attrition between treat-
ment groups, and total attrition was not significantly
related to baseline characteristics. Also, the primary ana-
lyses were ITT analyses based on the randomization
groups.
For some of the outcome measures, the sample size
may have been too small to detect actual differences
among the drugs, resulting in type II errors. This may
particularly be true for the survival outcomes. In
Johnsen et al. BMC Psychiatry 2010, 10:26
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Page 11 of 13addition the high rate of dropouts through follow-up led
to much censoring resulting in less statistical power.
The symptom outcomes and tolerability outcomes are
less vulnerable because of the statistical method used.
The naturalistic design aspires to mimic clinical practice
in which the antipsychotic treatment is initiated before the
diagnosis for a particular patient is specified although for
some of the SGAs this represents off-label use. Patients
were included consecutively because of psychosis per se,
and diagnostic evaluations were performed later by the
treating clinicians. Accordingly, the sample is heteroge-
neous with respect to diagnoses and duration of the psy-
chotic disorder among others, and there were insufficient
statistical power to perform secondary analyses in sub-
groups which limits the inference of trial results to
selected sub-populations suffering from psychosis.
F i n a l l y ,t h eC D S Sw a su s e dt oa s s e s ss y m p t o m so f
depression. The CDSS is primarily developed to assess
depression in patients with schizophrenia, and may not
be the optimal tool in assessing depressive features in
other diagnostic categories.
Conclusions
In this heterogeneous sample of patients acutely
admitted to hospital for symptoms of psychosis, the
quetiapine group was associated with the most beneficial
outcome in terms of reduction of the PANSS total
score; the PANSS positive subscale score; the PANSS
general psychopathology subscale score; the CGI-S
score; and in increasing the GAF-F score. There were
no substantial differences among the SGAs regarding
tolerability outcomes.
Additional file 1: Table S1. Baseline demographic and clinical
characteristics. Baseline demographic and clinical characteristics of the
Bergen Psychosis Project sample.
Additional file 2: Table S2. Symptoms outcomes. Comparisons
between risperidone, olanzapine, quetiapine, and ziprasidone groups
with regards to change of the scores of the Positive and Negative
Syndrome Scale scores; the Calgary Depression Scale for Schizophrenia;
the Global Assessment of Functioning scale - Split version, Functions
scale; and the Clinical Global Impression - Severity of Illness scale.
Additional file 3: Table S3. Tolerability outcomes. Comparisons
between risperidone, olanzapine, quetiapine, and ziprasidone groups
with regards to change of side effects and tolerability outcomes.
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